Evidence map›Paper›PMID 35578945›Full record

ReviewComprehensive Physiology2022

Physiological Systems in Promoting Frailty.

Laís R Perazza, Holly M Brown-Borg, LaDora V Thompson

Open access · greenAbstract readReview
In one paragraph

Review in Comprehensive Physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Laís R PerazzaDepartment of Physical Therapy and Athletic Training, Boston University, Boston, Massachusetts, USA.
Holly M Brown-BorgDepartment of Biomedical Sciences, University of North Dakota, Grand Forks, North Dakota, USA.
LaDora V ThompsonDepartment of Physical Therapy and Athletic Training, Boston University, Boston, Massachusetts, USA.
Boston University · USUniversity of North Dakota · US

Funding

Academic Leadership Award - The Translational Rehabilitation in Geroscience InitiativeK07AG072124 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI THOMPSON, LADORA V · 2021 to 2025
$790k
Frailty: Prediction of Onset and ProgressionR56AG067724 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BROWN-BORG, HOLLY M., THOMPSON, LADORA V · 2020 to 2020
$759k
NIA NIH HHS K07 AG072124NIA NIH HHS R56 AG067724
6 · The paper itself

Abstract

Frailty is a complex syndrome affecting a growing sector of the global population as medical developments have advanced human mortality rates across the world. Our current understanding of frailty is derived from studies conducted in the laboratory as well as the clinic, which have generated largely phenotypic information. Far fewer studies have uncovered biological underpinnings driving the onset and progression of frailty, but the stage is set to advance the field with preclinical and clinical assessment tools, multiomics approaches together with physiological and biochemical methodologies. In this article, we provide comprehensive coverage of topics regarding frailty assessment, preclinical models, interventions, and challenges as well as clinical frameworks and prevalence. We also identify central biological mechanisms that may be at play including mitochondrial dysfunction, epigenetic alterations, and oxidative stress that in turn, affect metabolism, stress responses, and endocrine and neuromuscular systems. We review the role of metabolic syndrome, insulin resistance and visceral obesity, focusing on glucose homeostasis, adenosine monophosphate-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and nicotinamide adenine dinucleotide (NAD

Indexed as

FrailtyInsulin ResistanceAgingHumansOxidative StressUnited States

Identifiers

PMID35578945
PMCPMC9531553
OpenAlexW4280640466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.